Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products
Elanco beat second-quarter estimates, raised 2026 guidance and cited strong Pet Health demand, Zenrelia growth and expanding margins.
Elanco sold more pet medicine and made more profit than people expected, so the company feels confident about the next couple of years. When a company beats its targets and raises its hopes for the future, it can mean the business is doing well—watch to see if they keep this momentum going.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.